17 Apr 2025
Ekarnia® Launches Groundbreaking Global Platform
Ekarnia® Launches Groundbreaking Global Platform to Transform Service Provider Discovery and Intelligence for the Pharmaceutical Industry
London (22nd April 2025)
After 24 months of focused development and deep industry collaboration, Ekarnia® today announces the official launch of the world’s first global platform dedicated to service provider intelligence for the pharmaceutical sector. Built by pharma, for pharma, Ekarnia redefines how pharmaceutical executives and procurement leaders identify, evaluate, and engage with specialist service providers.
In an industry where time-to-market, regulatory complexity, and operational precision are paramount, Ekarnia answers a critical and long-standing challenge: how to consistently find the right partner, for the right task, at the right time without relying on fragmented systems, anecdotal recommendations, or lengthy market reports.
A Platform Purpose-Built for Pharma
In today’s complex pharmaceutical landscape, selecting the right service provider is critical, but often inefficient. Traditional supplier discovery methods rely on outdated directories, informal networks, and static market reports. Ekarnia changes that.
Discovering the Right Partner, Faster – Powered by Ekarnia® Discovery
Ekarnia simplifies and accelerates the discovery process by providing pharma executives and procurement teams with access to over 4,000 pre-mapped agencies across 45 pharmaceutical service disciplines. With structured profiles and smart search functionality, users can quickly identify partners that align with specific therapeutic, functional, or geographic needs.
This not only streamlines partner selection but ensures decisions are rooted in transparent, up-to-date, and structured data, reducing guesswork and saving valuable time.
Unifying Strategic Supplier Insights – Enabled by Ekarnia® Intelligence
Ekarnia goes far beyond discovery.
The platform enables pharmaceutical companies to gain a unified, real-time view of their existing service provider ecosystem, providing deep insights into current partnerships. From capabilities and therapeutic focus to geographical expertise, commercial terms, track record, and case studies, Ekarnia consolidates key intelligence in one secure, accessible environment. This drives better-informed decisions at every stage of the partnership lifecycle, improving outcomes for all.
“We built Ekarnia because we understand the frustration of sourcing the right service provider for the right task. Pharma leaders deserve better than disconnected supplier data and decision-making based on limited insight. We’ve developed a platform that brings clarity, objectivity, and speed to one of the most critical operational decisions - who you choose to partner with.”
David Rowley, Executive Chairman, Ekarnia
Key Platform Features
Accessible to Ekarnia® Discovery and Ekarnia® Intelligence subscribers:
4,000+ mapped pharmaceutical service providers across 45 disciplines
Pre-populated profiles with up to 30 data fields
Smart filter and keyword search functionality
Shortlisting and supplier list capability
Exclusive to Ekarnia® Intelligence subscribers:
Supplier onboarding to verify and enrich their data for improved visibility
Capability endorsements, written reviews, and Net Promoter Scores from pharma users drive objective performance assessment
Secure, private libraries for partnership-level data (track records, case studies, commercial terms, etc.)
Performance analytics to support procurement decisions and risk management
Powered by Artificial Intelligence, Verified by Industry
At the core of Ekarnia is advanced AI, delivering high-quality, real-time supplier intelligence. Ekarnia continuously scans and synthesizes information to ensure pharma companies have access to the most relevant, objective, and up-to-date service provider data to inform their supplier decisions.
Ekarnia was developed in collaboration with industry leaders, with Bayer Pharma as its first enterprise client. The pharma heritage of the Founding Partner team including AbbVie, GSK, Eli Lilly, and Pfizer has further enhanced the platform features and capabilities.
“We are excited to engage with Ekarnia® to optimize how we discover and select agency partners across our global operations. The platform addresses the challenge of navigating a fragmented supplier landscape with limited transparency and inconsistent data. Ekarnia offers a more structured, intelligent, and scalable way to identify and manage the right partners for the right work.”
Alicia Macdonald, Global Commercial Procurement Lead, Bayer Pharma
Data-Driven Decision Making
With the global outsourced pharmaceutical commercialization market estimated at over £30 billion annually, the stakes for selecting the right partners have never been higher. Ekarnia offers a faster, smarter, and more objective approach. By reducing service provider discovery timelines, improving decision-making transparency, and providing one source of truth for capabilities and performance, Ekarnia can deliver up to $2 million in efficiency savings per organization per year.
About Ekarnia®
Ekarnia was founded to address the growing complexity and inefficiency of service provider discovery and intelligence in the pharmaceutical sector. With in-house experience from both pharmaceutical companies and agencies, the team behind Ekarnia spent over two years researching, testing, and building a platform designed to meet real-world needs. Focused solely on pharma, Ekarnia empowers organizations to move beyond outdated processes and make supplier decisions with confidence, clarity, and speed.
Contacts:
Charlotte Richards charlotterichards@ekarnia.com
Carwyn Jones carwynjones@ekarnia.com
David Rowley davidrowley@ekarnia.com